Chalcogen, Or Additional -c(=x), Bonded Directly To The Nitrogen Patents (Class 558/173)
  • Patent number: 10934604
    Abstract: The invention relates to the use, as an extraction agent for extracting at least one rare earth from an aqueous phase including phosphoric acid, of at least one compound of the following general formula (I): where n is an integer equal to 0, 1 or 2, R1 and R2 are H or an aliphatic hydrocarbon group, one of R3 and R4 has the following formula (II): where R5 and R6 are a hydrocarbon, hydroxyl or alkoxyl group, and the other one of R3 and R4 has one of the following formulas (II?) and (III): where R5? and R6? are a hydrocarbon, hydroxyl or alkoxyl group, and R7 and R8 are H or an aliphatic hydrocarbon group. The invention also relates to a method for recovering at least one rare earth using said compound, as well as to specific compounds as such.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: March 2, 2021
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Fanny Mary, Guilhem Arrachart, Stephane Pellet-Rostaing, Antoine Leydier, Veronique Dubois
  • Publication number: 20140378418
    Abstract: In particular, the compound is effective to inhibit Dxr in Mycobacterium tuberculosis (Mtb). The present invention relates to compounds having general formula (I) or (II) where X is an acidic group, such as carboxylate, phosphonate, sulfate, and tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, preferably 2, 3, or 4. The compounds inhibits 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr), particularly Dxr in Mycobacterium tuberculosis (Mtb).
    Type: Application
    Filed: June 29, 2012
    Publication date: December 25, 2014
    Inventors: Helena I. Boshoff, Cynthia S. Dowd, Emily R. Jackson, Kylene Kehn-Hall, Richard E. Lee, Robin Lee, Geraldine San Jose
  • Publication number: 20140163136
    Abstract: Hydrophilic, biocidal coating compositions and methods to make and use the compositions are disclosed. The coatings include compounds with quaternary amine polyethylene glycol groups and polyaminoalkyl biguanide groups as substituents. The compounds when incorporated in paints provide hydrophilic, self-cleaning and biocidal property to the coating.
    Type: Application
    Filed: December 10, 2012
    Publication date: June 12, 2014
    Applicant: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventors: Glen Leon Brizius, Phillip Kent Montgomery
  • Publication number: 20130284944
    Abstract: An object of the present invention is to provide an insulator which can suppress quenching between fluorescent dyes and enhance fluorescence intensity. The present invention provides, in order to achieve this object, an insulator which contains a ring entity of nonplanar structure and suppresses reduction in fluorescence intensity of one or two or more fluorescent labels adjacent to the insulator.
    Type: Application
    Filed: February 28, 2011
    Publication date: October 31, 2013
    Applicant: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Hiromu Kashida, Hiroyuki Asanuma, Koji Sekiguchi, Naofumi Higashiyama
  • Publication number: 20130131311
    Abstract: Improved methods of native chemical ligation are provided. The methods involve reacting a thioacid (e.g. a peptide thioacid) with an aziridinyl compound (e.g. an aziridinyl peptide) under mild conditions without the use of protecting groups, and without requiring that a cysteine residue be present in the ligation product. Initial coupling of the thioacid and the aziridinyl compound yields a ligation product which contains an aziridinyl ring. Subsequent opening of the aziridinyl ring (e.g. via a nucleophilic attack) produces a linearized and modified ligation product.
    Type: Application
    Filed: November 13, 2012
    Publication date: May 23, 2013
    Applicant: WASHINGTON STATE UNIVERSITY
    Inventor: Washington State University
  • Publication number: 20120214769
    Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: April 8, 2011
    Publication date: August 23, 2012
    Applicant: METABASIS THERAPEUTICS, INC.
    Inventors: Jorge E. Gomez-Galeno, K. Raja Reddy, Paul D. van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo
  • Publication number: 20120202777
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives of Formula I, wherein the variables G, T, D, L, A, X, R1 and R2 are as described hereinabove, and their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
    Type: Application
    Filed: October 4, 2010
    Publication date: August 9, 2012
    Inventors: Matthew Frank Brown, Anthony Marfat, Michael Joseph Melnick, Usa Reilly
  • Publication number: 20090253926
    Abstract: The present invention provides processes for synthesizing lysine based compounds of the formula; wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, wherein X may be, for example, NH2, Y may be H, F, Cl, or Br, and wherein n, X?, Y?, R2, R3, R4, R5 and R6 are as defined herein.
    Type: Application
    Filed: June 19, 2008
    Publication date: October 8, 2009
    Applicant: Ambrilla Biopharma Inc.
    Inventors: Guy Milot, Stephane Branchaud, Brent R. Stranix
  • Publication number: 20090093612
    Abstract: The present invention provides amide-substituted xanthene fluorescent dyes and reagent for the introduction of phosphonate or sulfo groups into the fluorescent dyes.
    Type: Application
    Filed: October 2, 2008
    Publication date: April 9, 2009
    Applicant: Epoch Biosciences, Inc.
    Inventor: Eugene Lukhtanov
  • Publication number: 20080194843
    Abstract: Crosslinkers having a covalently bonded phosphorous atom, the phosphorous atom having at least one covalently bonded oxygen atom. Crosslinkers can be used with resins such as epoxy, acrylic, polyurethane, polycarbonate, polysiloxane, polyvinyl, polyether, aminoplast, and polyester resins. A process to produce a crosslinker includes incorporating a pendent group comprising a covalently bonded phosphorous atom.
    Type: Application
    Filed: February 8, 2007
    Publication date: August 14, 2008
    Applicant: BASF CORPORATION
    Inventors: Sergio GONZALEZ, Timothy S. December
  • Patent number: 7030103
    Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: April 18, 2006
    Assignee: Methylgene, Inc.
    Inventors: Jeffrey M. Besterman, Daniel Delorme, Jubrail Rahil
  • Patent number: 6353128
    Abstract: A class of novel phenyl acetamides is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: March 5, 2002
    Assignee: Eli Lilly and Company
    Inventors: Theodore Goodson, Jr., Richard Waltz Harper, David Kent Herron
  • Patent number: 6242433
    Abstract: The present invention relates to novel geranylgeranyl derivatives and the pharmaceutically acceptable salts thereof having antiproliferative activity in eukaryotic cells with respect to the inhibition of protein geranygeranylation. The invention also relates to the pharmaceutical compositions containing the novel derivatives and to the process of preparation thereof.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: June 5, 2001
    Assignee: Laboratori Baldacci SpA
    Inventors: Aldo Balsamo, Bruno Macchia, Marco Macchia, Massimo Baldacci, Romano Danesi, Mario Del Tacca
  • Patent number: 6136798
    Abstract: The present invention provides compounds that inhibit the association of platelet-derived growth factor and phosphatidylinositol 3-kinase. The present invention also provides pharmaceutical compositions that contain a compound that inhibits the association of platelet-derived growth factor and phosphatidylinosital 3-kinase, and methods of treating cancer, restenosis, arthritis, dermatitis, atherosclerosis, vein graft intimal hyperplasia, neointimal hyperplasia of vascular smooth muscle and psoriasis using compounds that inhibit the association of platelet-derived growth factor and phosphatidylinositol 3-kinase.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: October 24, 2000
    Assignee: Warner-Lambert Company
    Inventors: Wayne Livingston Cody, Annette Marian Doherty, Scott R. Eaton, Robert Lee Panek
  • Patent number: 5824661
    Abstract: Compounds of the formula ##STR1## where m and n are integers 0 to 10 and m+n equals 0 to 10, (a) X is O or S(b) Z is a covalent bond; a monocyclic or polycyclic carbocycle ring moiety; or a monocyclic or polycyclic heterocyclic ring moiety containing one or more heteroatoms selected from O, S, or N;(c) Q is covalent bond; O; or S;(d) R is COOH, SO.sub.3 H, PO.sub.3 H.sub.2, or P(O)(OH)R.sup.4, wherein R.sup.4 is C.sub.1 -C.sub.8 alkyl;(e) R.sup.1, R.sup.2 and R.sup.5 are as defined in the claims.are useful in the treatment of calcium and phosphate elated disorders, such as arthritis and the like.
    Type: Grant
    Filed: September 7, 1994
    Date of Patent: October 20, 1998
    Assignee: The Procter & Gamble Company
    Inventors: Marion David Francis, Susan Mary Kaas, Frank Hallock Ebetino
  • Patent number: 5741923
    Abstract: An improved process for producing ethylenically unsaturated phosphate ester compounds, especially 2-(methacryloyloxyethyl)-2' (trimethylammoniomethyl) phosphate, (HEMA-PC) comprises a two step reaction in the first of which a phospholane reagent is reacted with a hydroxyl containing ethylenically unsaturated starting material, and in the second of which the intermediate formed in the first step is ring opened by reaction with trimethylamine to produce a zwitterionic product. In the process the two steps of the reaction are carried out in the same solvent with substantially no removal or addition of solvent after the first step. The solvent is preferably acetonitrile. The use of pure reagents avoids the production of undesirable by-products. The product is suitable for polymerising, for instance to provide cross-linked hydrogel copolymers used in ophthalmic applications.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: April 21, 1998
    Assignee: Biocompatibles Limited
    Inventors: Michael John Driver, Deborah Jane Jackson
  • Patent number: 5637577
    Abstract: Phospholipid derivatives containing higher elements of the Vth main group (P, As, Sb, Bi), their method of preparation and antineoplastic and antimicrobially active medications that can be prepared from the phospholipid derivatives.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: June 10, 1997
    Assignee: Asta Medica Aktiengesellschaft
    Inventors: Gerhard Nossner, Jurij Stekar, Peter Hilgard, Bernhard Kutscher, Jurgen Engel
  • Patent number: 5449798
    Abstract: Phospholipid derivatives containing higher elements of the Vth main group (P, As, Sb, Bi), their method of preparation and antineoplastic and antimicrobially active medications that can be prepared from the phospholipid derivatives.
    Type: Grant
    Filed: September 22, 1993
    Date of Patent: September 12, 1995
    Assignee: Asta Medica Aktiengesellschaft
    Inventors: Gerhard Nossner, Jurij Stekar, Peter Hilgard, Bernhard Kutscher, Jurgen Engel
  • Patent number: 5424474
    Abstract: The present invention relates to fluorinated carboxylic acid esters of phosphono- and phosphinocarboxylic acids containing hydroxyl and/or mercapto groups, their use as waterproofing and/or oil-repellency agents, and a method for their preparation.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: June 13, 1995
    Assignee: Bayer AG
    Inventors: Klaus Pohmer, Rainer Weber, Hans-Dieter Block, Hans-Heinrich Moretto
  • Patent number: 5414102
    Abstract: The present invention relates to fluorinated carboxylic acid esters of phosphonocarboxylic acids containing acrylate and/or methacrylate groups, their use as waterproofing or oil-repellency agents, and a method for their preparation.
    Type: Grant
    Filed: December 27, 1993
    Date of Patent: May 9, 1995
    Assignee: Bayer Aktiengesellschaft
    Inventors: Klaus Pohmer, Rainer Weber, Hans-Dieter Block, Hans-Heinrich Moretto
  • Patent number: 5362899
    Abstract: A stereospecific method of preparing alpha-aminophosphonic acids and derivatives thereof is provided. A protected amino acid is converted to a acyl aroyl or diacyl peroxide which spontaneously rearranges to form an alpha-amino ester. This rearrangement occurs stereospecifically with retention of configuration. The ester is subsequently converted to an appropriate leaving group and displaced with a phosphite yielding a chiral alpha-aminophosphonic acid or derivative.Alpha-aminophosphonic acids are useful for the synthesis of peptide analogs that possess a phosphonate linkage in the place of an amide linkage. This substitution can impart protease resistance in therapeutic peptides thereby increasing the serum half-life.
    Type: Grant
    Filed: September 9, 1993
    Date of Patent: November 8, 1994
    Assignee: Affymax Technologies, N.V.
    Inventor: David A. Campbell
  • Patent number: 5344930
    Abstract: Compounds of the general formula: ##STR1## are useful as surfactants in the preparation of fluorocarbon emulsions, which can be used as oxygen-carrying blood substitutes, and for many other therapeutic and diagnostic applications. They are further useful in liposomal formulations which are themselves therapeutic agents or provide a vehicle for such agents.
    Type: Grant
    Filed: November 8, 1993
    Date of Patent: September 6, 1994
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Jean G. Riess, Francois Jeanneaux, Marie-Pierre Krafft, Catherine Santaella, Pierre Vierling
  • Patent number: 5051413
    Abstract: The invention relates to unsaturated amino acids of the formula I ##STR1## in which R.sup.1 represents hydroxy or etherified hydroxy, R.sup.2 represents hydrogen, alkyl, hydroxy or etherified hydroxy, R.sup.3 represents hydrogen, alkyl, haloalkyl, hydroxyalkyl, lower alkoxyalkyl, arylalkyl, lower alkenyl, halogen or aryl, R.sup.4 represents hydrogen, alkyl or aryl, R.sup.5 represents hydrogen or alkyl, R.sup.6 represents carboxy or esterified or amidated carboxy, R.sup.7 represents amino or amino substituted by alkyl or acyl, A represents unsubstituted or alkyl-substituted .alpha.,.omega.-alkylene having from 1 to 3 carbon atoms or represents a bond, and B represents methylene or a bond, with the proviso that A is other than a bond when B represents a bond, and salts thereof. They can be manufactured, for example, in accordance with the Michaelis-Arbuzov reaction and can be used as pharmacologically active substances.
    Type: Grant
    Filed: December 18, 1989
    Date of Patent: September 24, 1991
    Assignee: Ciba-Geigy Corporation
    Inventors: Christof Angst, Derek E. Brundish, John G. Dingwall, Graham E. Fagg, Hans Allgeier, Guido Bold, Rudolf Duthaler, Roland Heckendorn, Antonio Togni
  • Patent number: 4686209
    Abstract: Compounds of the formula ##STR1## wherein the symbols have assigned meanings, and their use for controlling insects and mites.
    Type: Grant
    Filed: January 10, 1986
    Date of Patent: August 11, 1987
    Assignee: E. I. Du Pont de Nemours and Company
    Inventor: Mohamed A. H. Fahmy
  • Patent number: 4675429
    Abstract: Herbicidal compounds of formula: ##STR1## in which R.sup.1 denotes an optionally halogenated alkyl radical containing from 1 to 4 carbon atoms,R denotes the hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms,R.sup.2 denotes the hydrogen atom or R21,R.sup.21 and R.sup.3 denote optionally substituted aryl radicals,R.sup.4 denotes a hydrogen atom or a hydrogenolysable group R.sup.8,and the agriculturally acceptable salts of these compounds.
    Type: Grant
    Filed: January 14, 1986
    Date of Patent: June 23, 1987
    Assignee: Rhone-Poulenc Agrochimie
    Inventors: Guy Borrod, Guy Lacroix
  • Patent number: 4579691
    Abstract: When applied as safeners, the haloacylaminoalkylphosphinates, haloacylaminoalkylphosphinates and haloacylaminoalkylphosphine oxides of the formula I below are able to protect cultivated plants from the phytotoxic effects of herbicides. Suitable crops are preferably sorghum, cereals, rice, maize and soya beans and the herbicides employed are chloroacetanilides and thiocarbamates.The haloacylaminoalkylphosphonates, haloacylaminoalkylphosphinates and haloacylaminoalkylphosphine oxides have the formula I ##STR1## wherein R.sub.1 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkenyloxy, C.sub.2 -C.sub.4 alkynyloxy, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkoxy or C.sub.1 -C.sub.4 cyanoalkoxy,R.sub.2 is hydrogen or a substituent as defined for R.sub.1,R.sub.3 and R.sub.4 are each independently hydrogen, C.sub.1 -C.sub.4 alkyl or one of R.sub.3 and R.sub.4 is also a radical ##STR2## or both taken together with the carbon atom to which they are attached are also a C.sub.3 -C.sub.
    Type: Grant
    Filed: April 11, 1984
    Date of Patent: April 1, 1986
    Assignee: Ciba-Geigy Corporation
    Inventors: Ludwig Maier, Hans Moser